ID   GAS6_HUMAN              Reviewed;         678 AA.
AC   Q14393; B3KRQ7; B3KVL4; E9PBL7; Q6IMN1; Q7Z7N3;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   12-SEP-2018, sequence version 3.
DT   18-JUN-2025, entry version 230.
DE   RecName: Full=Growth arrest-specific protein 6 {ECO:0000305};
DE            Short=GAS-6;
DE   AltName: Full=AXL receptor tyrosine kinase ligand;
DE   Flags: Precursor;
GN   Name=GAS6 {ECO:0000312|HGNC:HGNC:4168}; Synonyms=AXLLG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=8336730; DOI=10.1128/mcb.13.8.4976-4985.1993;
RA   Manfioletti G., Brancolini C., Avanzi G., Schneider C.;
RT   "The protein encoded by a growth arrest-specific gene (gas6) is a new
RT   member of the vitamin K-dependent proteins related to protein S, a negative
RT   coregulator in the blood coagulation cascade.";
RL   Mol. Cell. Biol. 13:4976-4985(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15108283; DOI=10.1002/humu.20025;
RA   Munoz X., Sumoy L., Ramirez-Lorca R., Villar J., de Frutos P.G., Sala N.;
RT   "Human vitamin K-dependent GAS6: gene structure, allelic variation, and
RT   association with stroke.";
RL   Hum. Mutat. 23:506-512(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3; 4 AND 5).
RC   TISSUE=Kidney, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-41; TYR-231; MET-347;
RP   ARG-500; LEU-580; LYS-612 AND GLN-616.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Fetal lung, and Fetal spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-85.
RA   Maree A.O., Hillmann A., McRedmond J.P., Fitzgerald D.J.;
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   RECEPTOR INTERACTION.
RX   PubMed=7854420; DOI=10.1038/373623a0;
RA   Varnum B.C., Young C., Elliott G., Garcia A., Bartley T.D., Fridell Y.W.,
RA   Hunt R.W., Trail G., Clogston C., Toso R.J., Yanagihara D., Bennett L.,
RA   Silber M., Merewether L.A., Tseng A., Escobar E., Liu E.T., Yamane H.K.;
RT   "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein
RT   encoded by growth-arrest-specific gene 6.";
RL   Nature 373:623-626(1995).
RN   [9]
RP   RECEPTOR INTERACTION.
RX   PubMed=7867073; DOI=10.1016/0092-8674(95)90520-0;
RA   Stitt T.N., Conn G., Gore M., Lai C., Bruno J., Radziejewski C.,
RA   Mattsson K., Fisher J., Gies D.R., Jones P.F., Masiakowski P., Ryan T.E.,
RA   Tobkes N.J., Chen D.H., DiStefano P.S., Long G.L., Basilico C.,
RA   Goldfarb M.P., Lemke G., Glass D.J., Yancopoulos G.D.;
RT   "The anticoagulation factor protein S and its relative, Gas6, are ligands
RT   for the Tyro 3/Axl family of receptor tyrosine kinases.";
RL   Cell 80:661-670(1995).
RN   [10]
RP   ALTERNATIVE SPLICING (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=9326368; DOI=10.1016/s0014-5793(97)01094-6;
RA   Marcandalli P., Gostissa M., Varnum B., Goruppi S., Schneider C.;
RT   "Identification and tissue expression of a splice variant for the growth
RT   arrest-specific gene gas6.";
RL   FEBS Lett. 415:56-58(1997).
RN   [11]
RP   RECEPTOR INTERACTION.
RX   PubMed=8939948; DOI=10.1074/jbc.271.47.30022;
RA   Nagata K., Ohashi K., Nakano T., Arita H., Zong C., Hanafusa H., Mizuno K.;
RT   "Identification of the product of growth arrest-specific gene 6 as a common
RT   ligand for Axl, Sky, and Mer receptor tyrosine kinases.";
RL   J. Biol. Chem. 271:30022-30027(1996).
RN   [12]
RP   RECEPTOR INTERACTION, SUBCELLULAR LOCATION, AND PROTEOLYTIC PROCESSING.
RX   PubMed=9326369; DOI=10.1016/s0014-5793(97)01093-4;
RA   Goruppi S., Yamane H., Marcandalli P., Garcia A., Clogston C., Gostissa M.,
RA   Varnum B., Schneider C.;
RT   "The product of a gas6 splice variant allows the release of the domain
RT   responsible for Axl tyrosine kinase receptor activation.";
RL   FEBS Lett. 415:59-63(1997).
RN   [13]
RP   FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY.
RX   PubMed=12364394; DOI=10.1161/01.res.0000036753.50601.e9;
RA   D'Arcangelo D., Gaetano C., Capogrossi M.C.;
RT   "Acidification prevents endothelial cell apoptosis by Axl activation.";
RL   Circ. Res. 91:E4-12(2002).
RN   [14]
RP   FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY.
RX   PubMed=18840707; DOI=10.1182/blood-2008-05-157073;
RA   Park I.K., Giovenzana C., Hughes T.L., Yu J., Trotta R., Caligiuri M.A.;
RT   "The Axl/Gas6 pathway is required for optimal cytokine signaling during
RT   human natural killer cell development.";
RL   Blood 113:2470-2477(2009).
RN   [15]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=21501828; DOI=10.1016/j.chom.2011.03.012;
RA   Morizono K., Xie Y., Olafsen T., Lee B., Dasgupta A., Wu A.M., Chen I.S.;
RT   "The soluble serum protein Gas6 bridges virion envelope phosphatidylserine
RT   to the TAM receptor tyrosine kinase Axl to mediate viral entry.";
RL   Cell Host Microbe 9:286-298(2011).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=23084921; DOI=10.1016/j.chom.2012.08.009;
RA   Meertens L., Carnec X., Lecoin M.P., Ramdasi R., Guivel-Benhassine F.,
RA   Lew E., Lemke G., Schwartz O., Amara A.;
RT   "The TIM and TAM families of phosphatidylserine receptors mediate dengue
RT   virus entry.";
RL   Cell Host Microbe 12:544-557(2012).
RN   [17]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=17005688; DOI=10.1128/jvi.01157-06;
RA   Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K., Irimura T.,
RA   Jones S., Feldmann H., Kawaoka Y.;
RT   "Tyro3 family-mediated cell entry of Ebola and Marburg viruses.";
RL   J. Virol. 80:10109-10116(2006).
RN   [18]
RP   PHOSPHORYLATION AT SER-71.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 261-678, MUTAGENESIS OF PHE-487;
RP   LEU-620 AND TYR-660, AND INTERACTION WITH AXL.
RX   PubMed=8621659; DOI=10.1074/jbc.271.16.9785;
RA   Mark M.R., Chen J., Hammonds R.G., Sadick M., Godowski P.J.;
RT   "Characterization of Gas6, a member of the superfamily of G domain-
RT   containing proteins, as a ligand for Rse and Axl.";
RL   J. Biol. Chem. 271:9785-9789(1996).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 261-678 IN COMPLEX WITH AXL,
RP   SUBUNIT, GLYCOSYLATION AT ASN-420, AND MUTAGENESIS OF ARG-310 AND LYS-312.
RX   PubMed=16362042; DOI=10.1038/sj.emboj.7600912;
RA   Sasaki T., Knyazev P.G., Clout N.J., Cheburkin Y., Goehring W., Ullrich A.,
RA   Timpl R., Hohenester E.;
RT   "Structural basis for Gas6-Axl signalling.";
RL   EMBO J. 25:80-87(2006).
CC   -!- FUNCTION: Ligand for tyrosine-protein kinase receptors AXL, TYRO3 and
CC       MER whose signaling is implicated in cell growth and survival, cell
CC       adhesion and cell migration. GAS6/AXL signaling plays a role in various
CC       processes such as endothelial cell survival during acidification by
CC       preventing apoptosis, optimal cytokine signaling during human natural
CC       killer cell development, hepatic regeneration, gonadotropin-releasing
CC       hormone neuron survival and migration, platelet activation, or
CC       regulation of thrombotic responses. {ECO:0000269|PubMed:12364394,
CC       ECO:0000269|PubMed:18840707}.
CC   -!- FUNCTION: (Microbial infection) Can bridge virus envelope
CC       phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate
CC       viral entry by apoptotic mimicry (PubMed:21501828). Plays a role in
CC       Dengue cell entry by apoptotic mimicry (PubMed:23084921). Plays a role
CC       in Vaccinia virus cell entry by apoptotic mimicry (PubMed:21501828).
CC       Plays a role in ebolavirus and marburgvirus cell entry by apoptotic
CC       mimicry (PubMed:17005688). {ECO:0000269|PubMed:17005688,
CC       ECO:0000269|PubMed:21501828, ECO:0000269|PubMed:23084921}.
CC   -!- SUBUNIT: Heterodimer and heterotetramer with AXL.
CC       {ECO:0000269|PubMed:16362042}.
CC   -!- INTERACTION:
CC       Q14393-2; P30530: AXL; NbExp=8; IntAct=EBI-21517417, EBI-2850927;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:9326369}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q14393-2; Sequence=Displayed;
CC       Name=2; Synonyms=gas6SV {ECO:0000303|PubMed:9326368};
CC         IsoId=Q14393-1; Sequence=VSP_059770;
CC       Name=3;
CC         IsoId=Q14393-3; Sequence=VSP_059769;
CC       Name=4;
CC         IsoId=Q14393-4; Sequence=VSP_059768;
CC       Name=5;
CC         IsoId=Q14393-5; Sequence=VSP_059767;
CC   -!- TISSUE SPECIFICITY: Plasma. Isoform 1 and isoform 2 are widely
CC       expressed, isoform 1 being expressed at higher levels than isoform 2 in
CC       most tissues. Isoform 2 is the predominant form in spleen.
CC       {ECO:0000269|PubMed:8336730, ECO:0000269|PubMed:9326368}.
CC   -!- PTM: [Isoform 2]: Proteolytically processed after secretion to yield a
CC       N-terminal 36 kDa protein and a C-terminal 50 kDa protein including the
CC       laminin G-like domains which activates AXL.
CC       {ECO:0000269|PubMed:9326369}.
CC   -!- PTM: Gamma-carboxyglutamate residues are formed by vitamin K dependent
CC       carboxylation. These residues are essential for the binding of calcium.
CC       {ECO:0000255|PROSITE-ProRule:PRU00463}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L13720; AAA58494.1; -; mRNA.
DR   EMBL; AY256843; AAO84057.1; -; Genomic_DNA.
DR   EMBL; AY256830; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256831; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256832; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256833; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256834; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256835; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256836; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256837; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256838; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256839; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256840; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256841; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AY256842; AAO84057.1; JOINED; Genomic_DNA.
DR   EMBL; AK092028; BAG52469.1; -; mRNA.
DR   EMBL; AK122969; BAG53826.1; -; mRNA.
DR   EMBL; AK126533; BAC86580.1; -; mRNA.
DR   EMBL; AK290803; BAF83492.1; -; mRNA.
DR   EMBL; EF631974; ABR09277.1; -; Genomic_DNA.
DR   EMBL; BX072579; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC038984; AAH38984.1; -; mRNA.
DR   EMBL; AY170372; AAO41859.1; -; Genomic_DNA.
DR   EMBL; BK001240; DAA01155.1; -; Genomic_DNA.
DR   CCDS; CCDS45072.1; -. [Q14393-2]
DR   PIR; B48089; B48089.
DR   RefSeq; NP_000811.1; NM_000820.4. [Q14393-2]
DR   PDB; 1H30; X-ray; 2.20 A; A=261-678.
DR   PDB; 2C5D; X-ray; 3.30 A; A/B=261-678.
DR   PDB; 4RA0; X-ray; 3.07 A; A/B=279-678.
DR   PDB; 5VXZ; X-ray; 2.30 A; A/B=281-675.
DR   PDBsum; 1H30; -.
DR   PDBsum; 2C5D; -.
DR   PDBsum; 4RA0; -.
DR   PDBsum; 5VXZ; -.
DR   AlphaFoldDB; Q14393; -.
DR   SMR; Q14393; -.
DR   BioGRID; 108891; 140.
DR   FunCoup; Q14393; 717.
DR   IntAct; Q14393; 76.
DR   MINT; Q14393; -.
DR   STRING; 9606.ENSP00000331831; -.
DR   BindingDB; Q14393; -.
DR   ChEMBL; CHEMBL4804247; -.
DR   GlyCosmos; Q14393; 1 site, No reported glycans.
DR   GlyGen; Q14393; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; Q14393; -.
DR   PhosphoSitePlus; Q14393; -.
DR   BioMuta; GAS6; -.
DR   DMDM; 48427995; -.
DR   jPOST; Q14393; -.
DR   MassIVE; Q14393; -.
DR   PaxDb; 9606-ENSP00000331831; -.
DR   PeptideAtlas; Q14393; -.
DR   ProteomicsDB; 19251; -.
DR   ProteomicsDB; 59975; -. [Q14393-1]
DR   ProteomicsDB; 59976; -. [Q14393-2]
DR   ProteomicsDB; 59977; -. [Q14393-3]
DR   ProteomicsDB; 59978; -. [Q14393-4]
DR   Pumba; Q14393; -.
DR   Antibodypedia; 1292; 422 antibodies from 33 providers.
DR   DNASU; 2621; -.
DR   Ensembl; ENST00000327773.7; ENSP00000331831.6; ENSG00000183087.15. [Q14393-2]
DR   GeneID; 2621; -.
DR   KEGG; hsa:2621; -.
DR   MANE-Select; ENST00000327773.7; ENSP00000331831.6; NM_000820.4; NP_000811.1.
DR   UCSC; uc001vud.4; human. [Q14393-2]
DR   AGR; HGNC:4168; -.
DR   CTD; 2621; -.
DR   DisGeNET; 2621; -.
DR   GeneCards; GAS6; -.
DR   HGNC; HGNC:4168; GAS6.
DR   HPA; ENSG00000183087; Low tissue specificity.
DR   MIM; 600441; gene.
DR   OpenTargets; ENSG00000183087; -.
DR   VEuPathDB; HostDB:ENSG00000183087; -.
DR   eggNOG; ENOG502QT2N; Eukaryota.
DR   GeneTree; ENSGT00940000161271; -.
DR   HOGENOM; CLU_026236_0_0_1; -.
DR   InParanoid; Q14393; -.
DR   OMA; PIINHGM; -.
DR   OrthoDB; 4062651at2759; -.
DR   PAN-GO; Q14393; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; Q14393; -.
DR   PathwayCommons; Q14393; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-159740; Gamma-carboxylation of protein precursors.
DR   Reactome; R-HSA-159763; Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus.
DR   Reactome; R-HSA-159782; Removal of aminoterminal propeptides from gamma-carboxylated proteins.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   SignaLink; Q14393; -.
DR   SIGNOR; Q14393; -.
DR   BioGRID-ORCS; 2621; 14 hits in 1160 CRISPR screens.
DR   ChiTaRS; GAS6; human.
DR   EvolutionaryTrace; Q14393; -.
DR   GeneWiki; GAS6; -.
DR   GenomeRNAi; 2621; -.
DR   Pharos; Q14393; Tbio.
DR   PRO; PR:Q14393; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; Q14393; protein.
DR   Bgee; ENSG00000183087; Expressed in ascending aorta and 199 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; IDA:UniProtKB.
DR   GO; GO:0048018; F:receptor ligand activity; IDA:UniProtKB.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IDA:UniProtKB.
DR   GO; GO:0032148; P:activation of protein kinase B activity; ISS:UniProtKB.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0043277; P:apoptotic cell clearance; IDA:UniProtKB.
DR   GO; GO:0035754; P:B cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; IEA:Ensembl.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0031589; P:cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0035457; P:cellular response to interferon-alpha; IDA:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; IEA:Ensembl.
DR   GO; GO:0071307; P:cellular response to vitamin K; IDA:UniProtKB.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IDA:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; IEP:UniProtKB.
DR   GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; IEA:Ensembl.
DR   GO; GO:0085029; P:extracellular matrix assembly; ISS:UniProtKB.
DR   GO; GO:0044346; P:fibroblast apoptotic process; IEA:Ensembl.
DR   GO; GO:0019064; P:fusion of virus membrane with host plasma membrane; IDA:UniProtKB.
DR   GO; GO:0097241; P:hematopoietic stem cell migration to bone marrow; IDA:UniProtKB.
DR   GO; GO:0033028; P:myeloid cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0070168; P:negative regulation of biomineral tissue development; IDA:UniProtKB.
DR   GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IDA:UniProtKB.
DR   GO; GO:0032692; P:negative regulation of interleukin-1 production; IDA:UniProtKB.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IDA:UniProtKB.
DR   GO; GO:0033033; P:negative regulation of myeloid cell apoptotic process; IEA:Ensembl.
DR   GO; GO:1900142; P:negative regulation of oligodendrocyte apoptotic process; IDA:UniProtKB.
DR   GO; GO:2000533; P:negative regulation of renal albumin absorption; ISS:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IDA:UniProtKB.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0032689; P:negative regulation of type II interferon production; IDA:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0006909; P:phagocytosis; IDA:UniProtKB.
DR   GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:2000510; P:positive regulation of dendritic cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:MGI.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0003104; P:positive regulation of glomerular filtration; ISS:UniProtKB.
DR   GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IDA:UniProtKB.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; IDA:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032008; P:positive regulation of TOR signaling; ISS:UniProtKB.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046813; P:receptor-mediated virion attachment to host cell; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0046718; P:symbiont entry into host cell; IDA:UniProtKB.
DR   GO; GO:0019079; P:viral genome replication; IDA:UniProtKB.
DR   CDD; cd00054; EGF_CA; 2.
DR   CDD; cd00110; LamG; 2.
DR   FunFam; 2.60.120.200:FF:000118; Growth arrest specific 6; 1.
DR   FunFam; 2.10.25.10:FF:000528; Growth arrest-specific protein 6; 1.
DR   FunFam; 2.10.25.10:FF:000550; Growth arrest-specific protein 6; 1.
DR   FunFam; 2.60.120.200:FF:000089; growth arrest-specific protein 6; 1.
DR   FunFam; 2.10.25.10:FF:000119; vitamin K-dependent protein S; 1.
DR   FunFam; 4.10.740.10:FF:000001; vitamin K-dependent protein S; 1.
DR   Gene3D; 2.60.120.200; -; 2.
DR   Gene3D; 4.10.740.10; Coagulation Factor IX; 1.
DR   Gene3D; 2.10.25.10; Laminin; 4.
DR   InterPro; IPR026823; cEGF.
DR   InterPro; IPR017857; Coagulation_fac-like_Gla_dom.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR051145; GAS-SHBG-PROS.
DR   InterPro; IPR035972; GLA-like_dom_SF.
DR   InterPro; IPR000294; GLA_domain.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR001791; Laminin_G.
DR   InterPro; IPR049883; NOTCH1_EGF-like.
DR   PANTHER; PTHR24040:SF14; GROWTH ARREST-SPECIFIC PROTEIN 6; 1.
DR   PANTHER; PTHR24040; LAMININ G-LIKE DOMAIN-CONTAINING PROTEIN; 1.
DR   Pfam; PF12662; cEGF; 1.
DR   Pfam; PF07645; EGF_CA; 1.
DR   Pfam; PF00594; Gla; 1.
DR   Pfam; PF12661; hEGF; 1.
DR   Pfam; PF00054; Laminin_G_1; 1.
DR   Pfam; PF02210; Laminin_G_2; 1.
DR   PRINTS; PR00001; GLABLOOD.
DR   SMART; SM00181; EGF; 4.
DR   SMART; SM00179; EGF_CA; 4.
DR   SMART; SM00069; GLA; 1.
DR   SMART; SM00282; LamG; 2.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 2.
DR   SUPFAM; SSF57196; EGF/Laminin; 1.
DR   SUPFAM; SSF57630; GLA-domain; 1.
DR   SUPFAM; SSF57184; Growth factor receptor domain; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 4.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 3.
DR   PROSITE; PS50026; EGF_3; 4.
DR   PROSITE; PS01187; EGF_CA; 3.
DR   PROSITE; PS00011; GLA_1; 1.
DR   PROSITE; PS50998; GLA_2; 1.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 2.
DR   neXtProt; NX_Q14393; -.
DR   PharmGKB; PA28582; -.
DR   TreeFam; TF352157; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Disulfide bond;
KW   EGF-like domain; Gamma-carboxyglutamic acid; Glycoprotein;
KW   Growth regulation; Host-virus interaction; Metal-binding; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL          1..30
FT                   /evidence="ECO:0000255"
FT   CHAIN           31..678
FT                   /note="Growth arrest-specific protein 6"
FT                   /id="PRO_0000007589"
FT   DOMAIN          53..94
FT                   /note="Gla"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00463"
FT   DOMAIN          116..154
FT                   /note="EGF-like 1; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          156..196
FT                   /note="EGF-like 2; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          197..237
FT                   /note="EGF-like 3; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          238..278
FT                   /note="EGF-like 4; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          298..470
FT                   /note="Laminin G-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          477..670
FT                   /note="Laminin G-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   BINDING         329
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         331
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         440
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         656
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   MOD_RES         71
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039"
FT   MOD_RES         621
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63772"
FT   MOD_RES         637
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63772"
FT   MOD_RES         640
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63772"
FT   CARBOHYD        420
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16362042"
FT   DISULFID        65..70
FT                   /evidence="ECO:0000250"
FT   DISULFID        120..133
FT                   /evidence="ECO:0000250"
FT   DISULFID        125..142
FT                   /evidence="ECO:0000250"
FT   DISULFID        144..153
FT                   /evidence="ECO:0000250"
FT   DISULFID        160..171
FT                   /evidence="ECO:0000250"
FT   DISULFID        167..180
FT                   /evidence="ECO:0000250"
FT   DISULFID        182..195
FT                   /evidence="ECO:0000250"
FT   DISULFID        201..212
FT                   /evidence="ECO:0000250"
FT   DISULFID        207..221
FT                   /evidence="ECO:0000250"
FT   DISULFID        223..236
FT                   /evidence="ECO:0000250"
FT   DISULFID        242..251
FT                   /evidence="ECO:0000250"
FT   DISULFID        247..260
FT                   /evidence="ECO:0000250"
FT   DISULFID        262..277
FT   DISULFID        283..570
FT   DISULFID        444..470
FT   DISULFID        643..670
FT   VAR_SEQ         1..299
FT                   /note="Missing (in isoform 5)"
FT                   /id="VSP_059767"
FT   VAR_SEQ         1..273
FT                   /note="Missing (in isoform 4)"
FT                   /id="VSP_059768"
FT   VAR_SEQ         1..94
FT                   /note="MAPSLSPGPAALRRAPQLLLLLLAAECALAALLPAREATQFLRPRQRRAFQV
FT                   FEEAKQGHLERECVEELCSREEAREVFENDPETDYFYPRYLD -> MCMCQASPPPAAL
FT                   AGCLLSSCVQPAREHGGAFSKAEWLSN (in isoform 3)"
FT                   /id="VSP_059769"
FT   VAR_SEQ         278
FT                   /note="E -> ELEAGWPCPRHRRDGSPAARPGRGAQGSRSEGHIPDRRGPRPWQ
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9326368"
FT                   /id="VSP_059770"
FT   VARIANT         41
FT                   /note="F -> L (in dbSNP:rs201378406)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038823"
FT   VARIANT         231
FT                   /note="S -> Y (in dbSNP:rs146159446)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038824"
FT   VARIANT         347
FT                   /note="V -> M (in dbSNP:rs144457857)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038825"
FT   VARIANT         500
FT                   /note="G -> R (in dbSNP:rs7992146)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038826"
FT   VARIANT         580
FT                   /note="S -> L (in dbSNP:rs79807310)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038827"
FT   VARIANT         612
FT                   /note="E -> K (in dbSNP:rs73583241)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038828"
FT   VARIANT         616
FT                   /note="R -> Q (in dbSNP:rs199700915)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_038829"
FT   MUTAGEN         310
FT                   /note="R->E: Strongly reduced affinity for AXL. Abolishes
FT                   phosphorylation of AXL."
FT                   /evidence="ECO:0000269|PubMed:16362042"
FT   MUTAGEN         312
FT                   /note="K->E: Strongly reduced affinity for AXL. Abolishes
FT                   phosphorylation of AXL."
FT                   /evidence="ECO:0000269|PubMed:16362042"
FT   MUTAGEN         487
FT                   /note="F->A: Decreases activation of AXL."
FT                   /evidence="ECO:0000269|PubMed:8621659"
FT   MUTAGEN         620
FT                   /note="L->A: Reduces affinity for AXL 15-fold and decreases
FT                   activation of AXL."
FT                   /evidence="ECO:0000269|PubMed:8621659"
FT   MUTAGEN         660
FT                   /note="Y->A: Reduces affinity for AXL 3-fold."
FT                   /evidence="ECO:0000269|PubMed:8621659"
FT   CONFLICT        356
FT                   /note="E -> K (in Ref. 3; BAG52469)"
FT                   /evidence="ECO:0000305"
FT   HELIX           264..266
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          268..271
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   TURN            272..275
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          276..279
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          294..296
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          307..310
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          313..315
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          320..327
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          330..339
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          343..351
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          354..361
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          364..373
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          376..378
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          380..386
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          388..395
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          398..404
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          409..413
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          416..418
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          420..425
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   HELIX           430..432
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          433..435
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          443..450
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   HELIX           457..463
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   HELIX           466..468
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          469..473
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          475..480
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          486..488
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          507..518
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          520..527
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   HELIX           528..530
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          532..541
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          545..547
FT                   /evidence="ECO:0007829|PDB:4RA0"
FT   STRAND          552..557
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          560..566
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   HELIX           569..571
FT                   /evidence="ECO:0007829|PDB:5VXZ"
FT   STRAND          575..582
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          585..590
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          596..599
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   HELIX           601..615
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          620..624
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          633..635
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          642..648
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   HELIX           655..657
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          658..661
FT                   /evidence="ECO:0007829|PDB:1H30"
FT   STRAND          665..668
FT                   /evidence="ECO:0007829|PDB:5VXZ"
SQ   SEQUENCE   678 AA;  74925 MW;  BB6D8AB0F6C48EA9 CRC64;
     MAPSLSPGPA ALRRAPQLLL LLLAAECALA ALLPAREATQ FLRPRQRRAF QVFEEAKQGH
     LERECVEELC SREEAREVFE NDPETDYFYP RYLDCINKYG SPYTKNSGFA TCVQNLPDQC
     TPNPCDRKGT QACQDLMGNF FCLCKAGWGG RLCDKDVNEC SQENGGCLQI CHNKPGSFHC
     SCHSGFELSS DGRTCQDIDE CADSEACGEA RCKNLPGSYS CLCDEGFAYS SQEKACRDVD
     ECLQGRCEQV CVNSPGSYTC HCDGRGGLKL SQDMDTCEDI LPCVPFSVAK SVKSLYLGRM
     FSGTPVIRLR FKRLQPTRLV AEFDFRTFDP EGILLFAGGH QDSTWIVLAL RAGRLELQLR
     YNGVGRVTSS GPVINHGMWQ TISVEELARN LVIKVNRDAV MKIAVAGDLF QPERGLYHLN
     LTVGGIPFHE KDLVQPINPR LDGCMRSWNW LNGEDTTIQE TVKVNTRMQC FSVTERGSFY
     PGSGFAFYSL DYMRTPLDVG TESTWEVEVV AHIRPAADTG VLFALWAPDL RAVPLSVALV
     DYHSTKKLKK QLVVLAVEHT ALALMEIKVC DGQEHVVTVS LRDGEATLEV DGTRGQSEVS
     AAQLQERLAV LERHLRSPVL TFAGGLPDVP VTSAPVTAFY RGCMTLEVNR RLLDLDEAAY
     KHSDITAHSC PPVEPAAA
//
